Abstract
The role of human behavior to thwart transmission of infectious diseases like COVID-19 is evident. Yet, many areas of psychological and behavioral science are limited in the ability to mobilize to address exponential spread or provide easily translatable findings for policymakers. Here we describe how integrating methods from operant and cognitive approaches to behavioral economics can provide robust policy relevant data. Adapting well validated methods from behavioral economic discounting and demand frameworks, we evaluate in four crowdsourced samples (total N = 1,366) behavioral mechanisms underlying engagement in preventive health behaviors. We find that people are more likely to social distance when specified activities are framed as high risk, that describing delay until testing (rather than delay until results) increases testing likelihood, and that framing vaccine safety in a positive valence improves vaccine acceptance. These findings collectively emphasize the flexibility of methods from diverse areas of behavioral science for informing public health crisis management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Dr. Strickland's work was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (T32 DA07209). Dr. Reed's work was supported by a General Research Fund award from the University of Kansas. Dr. Johnson's work was supported by NIDA grant R01 DA042527.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All studies were reviewed and approved by local Institutional Review Boards (University of Kansas or Johns Hopkins University). Participants reviewed a study cover letter to provide electronic informed consent prior to participation.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have no known conflicts of interest to disclose. Dr. Strickland’s work was supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (T32 DA07209). Dr. Reed’s work was supported by a General Research Fund award from the University of Kansas. Dr. Johnson’s work was supported by NIDA grant R01 DA042527.
Limited data set and code to replicate primary analyses is available at https://osf.io/wdnmx/?view_only=37323f9431aa4c91a0e7209054058dbe.
Author (Salzer) missing from medRxiv author list (was in document title page).
Data Availability
Limited data set and code to replicate primary analyses is available at https://osf.io/wdnmx/?view_only=37323f9431aa4c91a0e7209054058dbe.
https://osf.io/wdnmx/?view_only=37323f9431aa4c91a0e7209054058dbe
